Purpose: It is uncertain whether dexmedetomidine is better than propofol for sedation in postcardiac surgery patients. The purpose of this meta-analysis was to compare the effects of dexmedetomidine and propofol sedation on outcomes in adult patients after cardiac surgery. Methods: Randomized controlled trials comparing outcomes in cardiac surgery patients sedated with dexmedetomidine or propofol were retrieved from PubMed, Embase, Web of Science, the Cochrane Library, and Clinicaltrials.Gov until May 23, 2016. Results: A total of 969 patients in 8 studies met the selection criteria. The results revealed that dexmedetomidine was associated with a lower risk of delirium (risk ratio, 0.40;95% confidence interval [CI], 0.24-0.64; P = .0002), a shorter length of intubation (hours; mean difference, -0.95; 95% CI, -1.26 to -0.64; P b .00001), but a higher incidence of bradycardia (risk ratio 3.17; 95% CI, 1.41-7.10; P = .005) as compared to propofol. There were no statistical differences in the incidence of hypotension or atrial fibrillation, or the length of intensive care unit stay between dexmedetomidine and propofol sedation regimens. Conclusions: Dexmedetomidine sedation could reduce postoperative delirium and was associated with shorter length of intubation, but might increase bradycardia in patients after cardiac surgery compared with propofol.
Introduction
There are more than 2 million cardiac surgical procedures performed worldwide each year [1] . Although the mortality of cardiac surgical procedures has significantly decreased due to the great improvement in the surgical techniques, the major complication rates are as high as 14.4% to 30.1% [2] [3] [4] . These complications are associated with prolonged hospital stay, increase in resource utilization, and higher health care costs [5] . Thus, postoperative care of these patients remains to be optimized.
It is accepted that sedation is an important component of postoperative management after cardiac surgery [6] and has an important effect on patient outcomes [7] . Several studies, including 2 meta-analyses, have shown that dexmedetomidine is associated with a decrease in the incidences of postoperative complications in patients undergoing cardiac surgery [6, [8] [9] [10] [11] . However, 3 of these studies, including the 2 meta-analyses, did not directly compare dexmedetomidine with propofol [6, 8, 9] . Current guidelines suggest that sedation strategies using nonbenzodiazepine sedatives (either propofol or dexmedetomidine) may be preferred over sedation with benzodiazepines to improve clinical outcomes in mechanically ventilated adult intensive care unit (ICU) patients [7] . However, it is uncertain whether dexmedetomidine is better than propofol for sedation in patients after cardiac surgery. Therefore, we conducted a metaanalysis with trial sequential analysis (TSA) to evaluate the clinical effectiveness of dexmedetomidine sedation on improving outcomes in the patients after cardiac surgery compared with propofol.
ClinicalTrials.gov until May 23, 2016 . A basic search was performed using the following keywords: "dexmedetomidine" AND "propofol" AND ("cardiac surgery" OR "heart surgery" OR "coronary artery bypass grafting" OR "heart valve" OR "cardiopulmonary bypass") AND ("sedative" OR "sedation"). No language restriction was applied for the selection of articles.
Eligibility criteria
Eligible studies were of randomized controlled trials (RCTs), comparing dexmedetomidine with propofol for sedation in adult patients after cardiac surgery.
Data abstraction and quality assessment
Data were independently extracted by 2 reviewers and metaanalyzed according to predefined study selection criteria and clinical end points. The methodological quality of included studies was evaluated using the Cochrane risk of bias assessment tool as previously prescribed [12] . Disagreements on data abstraction and quality assessment between the 2 reviewers were resolved by a third reviewer. The abstracted data were as follows: first author, year of publication, region or country, surgery type, sample size, and details of sedation with dexmedetomidine and propofol (eg, sedation goal and drug dosages). The following adverse events were extracted if reported: delirium, hypotension, bradycardia, atrial fibrillation, ventricular tachycardia, nausea and vomiting, hyperglycemia, and any postoperative infection. In addition, length of intubation and duration of ICU and hospital stay were also extracted. The primary end point of the meta-analysis was the incidence of delirium, whereas secondary end points were the incidences of hypotension, bradycardia and atrial fibrillation, the length of intubation, and the duration of ICU stay. These end points were chosen because of their importance in clinical practice and frequency of being reported.
Statistical analysis
Treatment effects were reported as risk ratio (RR) with 95% confidence interval (CI) for adverse events or mean difference (MD) with 95% CI for length of intubation and duration of ICU and hospital stay. Analyses were performed using Review Manager 5.3 (The Cochrane Collaboration). We assessed the heterogeneity among studies using Cochran Q test (P b .10 for statistical significance) and the I 2 index (I 2 N 50% for substantial heterogeneity). If heterogeneity was absent, the fixed-effect model was chosen to calculate pooled effects; otherwise, a random-effect model was used. We used TSA to examine and minimize the impact of type 1 errors due to sparse data and repeated significance testing following updates with new trials [13] . The software TSA version 0.9 beta was used for these analyses [13] . P b .05 (2-sided) was regarded as statistically significant.
Results

Identifying eligible studies
The results of our search strategy are shown in Fig. 1 . We identified 503 titles, including 132 articles in PubMed, 146 articles in Web of Science, 141 articles in Embase, 57 articles in Cochrane Library, and 27 articles in ClinicalTrials.gov. Of these, 489 studies did not meet the inclusion criteria or were duplicates retrieved from the 4 databases and 1 Web site. We excluded studies on the bases of trial type, surgery type, and patient age. A total of 14 studies were reviewed, of which 8 publications met all selection criteria. However, 1 study data could not be extracted. Recently, we conducted a similar study [14] . Therefore, there were still 8 studies [10, 11, [14] [15] [16] [17] [18] [19] included in the meta-analysis and they reported 969 patients in all, of whom 481 were assigned to the dexmedetomidine group and 488 to the propofol group.
Description of the included papers
The details of surgery type, the number of patients, and the protocol of sedation of the included studies are presented in Table 1 . Four studies were coronary artery bypass grafting (CABG), 2 studies were valve surgery, and 2 studies were mixed cardiac surgery. The smallest study contained 55 patients [18] , whereas the largest study included 295 patients [16] . The overall quality of the trials is moderate, none of them met the "blinding of participants and personnel" bias criterion and thus were rated as high-risk (Table 2 ).
Outcomes of the pooled studies
The incidence of delirium was reported in the 4 RCTs [10, 11, 14, 15] . There were 18 (9.3%) of 193 patients with delirium in the dexmedetomidine group and 47 (23.5%) of 200 patients with delirium in the propofol group. Meta-analysis showed that the dexmedetomidine sedation significantly decreased postoperative delirium (POD; RR, 0.40; 95% CI, 0.24-0.64; P = .0002) (Fig. 2 ). Although the number of patients was small and therefore the quality of evidence is not high, TSA led us to upgrade the overall assessment (Fig. 3) .
Pooling of data from 5 studies [14] [15] [16] 18, 19] and another 6 studies [11, [14] [15] [16] [17] 19] showed that there was no difference in the incidence of hypotension or atrial fibrillation between dexmedetomidine and propofol sedation strategies, respectively (Figs. 4 and 5). However, when compared with propofol, dexmedetomidine sedation was associated with a higher risk of bradycardia (RR, 3.17; 95% CI, 1.41-7.10; P = .005) (Fig. 6 ) from the pooled results of 4 studies [14, 16, 18, 19] . These results were confirmed by TSA (Supplementary Electronic Material, Figs. E1, E2, and E3).
Seven studies reported the length of intubation as an outcome [10, 11, [14] [15] [16] 18, 19] . Meta-analysis showed that dexmedetomidine sedation might decrease the length of intubation compared with propofol (Fig. 7) . In the subgroup analysis, there was a significant difference in the length of intubation in the patients who underwent CABG between the dexmedetomidine and propofol sedation regimens (hours; MD, −0.98; 95% CI, −1.30 to −0.66; P b .00001) (Fig. 7) . However, there was no significant difference in the length of intubation in the patients who underwent valve surgery or mixed cardiac surgery between the 2 sedation regimens (Fig. 7) . The meta-analysis and TSA of the length of intubation both showed that the outcome was mainly affected by the study conducted by Karaman et al [19] ( Fig. 7 and Supplementary Electronic Material, Fig. E4 ).
In addition, a meta-analysis of 5 studies [10, 11, 14, 15, 18] of dexmedetomidine vs propofol found no difference in the duration of ICU stay (hours; MD, −9.72; 95% CI, −29.22 to 9.78; P = .33) (Fig. 8) , which was confirmed by TSA (Supplementary Electronic Material, Fig. E5 ). The heterogeneity of duration of ICU stay (I 2 = 78% and P = .001) is considerable among the included trials.
Publication bias and sensitivity analyses
We were unable to evaluate the publication bias due to the small number of the included studies in each comparison. Through performing a sensitivity analysis (the studies with "low risk" of "random sequence generation" and "allocation concealment"), the overall effect size was found to change minimally regardless of delirium or the length of intubation, but the incidence of bradycardia was found no difference between the dexmedetomidine and propofol sedation strategies (Table 3 ).
Discussion
This meta-analysis suggests that dexmedetomidine sedation may reduce delirium and the length of intubation, but may increase the risk of bradycardia in patients after cardiac surgery compared with propofol. There was no difference in the incidence of hypotension or atrial fibrillation, or the duration of ICU stay between the 2 sedation strategies.
Delirium is an acute mental disorder that involves changes in consciousness, attention, cognition, and perception [11] . Postoperative delirium occurs frequently in patients after cardiac surgery and is associated with prolonged hospital stay, higher costs, and increased morbidity and mortality [10, 11, 20] . Our results showed that dexmedetomidine sedation may reduce the incidence of POD compared with propofol. Several specific characteristics of dexmedetomidine may contribute to its effect on prevention of POD, such as follows: Fig. 3 . Trial sequential analysis of 4 trials of the effect of dexmedetomidine sedation on the incidence of delirium compared with propofol. Cumulative Z curve in blue does not cross the boundary of required information size (RIS; 1,036) in the meta-analysis (full red line with diamonds) with a relative risk reduction (RRR) of 60.43% (α = .05) and a power of 80% (β = 0.20). However, the cumulative Z curve breaks through the trial sequential monitoring boundary for favoring dexmedetomidine. The analysis therefore demonstrated that dexmedetomidine, as compared with propofol, had an intervention effect of an RRR of 60.43% with a power of 80% in 4 randomized trials with a total number of accrued participants of 393. dexmedetomidine improves the quality of sleep in critically ill patients, has opioid-sparing effect, is lacking anticholinergic activity, and attenuates the inflammatory response [9, 11] . Conversely, propofol, which acts by potentiating γ-aminobutyric acid type A receptors, has been implicated in the development and worsening of delirium [10] . Furthermore, unlike propofol, dexmedetomidine does not cause respiratory depression and could hypothetically improve weaning and shorten extubation times [6, 11] . Consequently, it is not surprising that the use of dexmedetomidine has increased over time in critically ill patients, especially in patients after cardiac surgery [21] .
Study or Subgroup
The study also showed that dexmedetomidine sedation shortened the length of intubation compared with propofol. However, there was a subgroup difference effect across different surgery types: CABG [15, 16, 19] (MD, −0.98; 95% CI, −1.30 to −0.66; P b .00001), valve surgery [10, 14] (MD, 0.30; 95% CI, −1.40 to 1.99; P = .73), and mixed cardiac surgery [11, 18] (MD, −1.70; 95% CI, −4.04 to 0.64; P = .15). The results revealed that dexmedetomidine might only facilitate early extubation in patients after CABG, which was similar to a previously published meta-analysis [9] . Compared with patients undergoing CABG, patients undergoing valve surgery or combined cardiac surgery are less fit and have higher incidence of complications [2] [3] [4] [22] [23] [24] , which may conceal the effect of dexmedetomidine sedation on shortening length of intubation. Further research is still needed to confirm this conclusion. In addition, the results of the meta-analysis did not support that dexmedetomidine sedation could reduce the duration of ICU stay compared with propofol in patients after cardiac surgery, even in patients after isolated CABG [15] . This may be due to the severity of illness and postoperative complications play the main role in determining the duration of ICU stay. Furthermore, the heterogeneity of the duration of ICU stay is considerable among the included trials, which may be attributed to different surgery types and primary outcomes in these trials and different clinical practices in these ICUs.
The most common adverse events associated with dexmedetomidine treatment are hypotension and bradycardia [6] . Our results showed that the incidence of hypotension was high in the dexmedetomidine group, but there was no difference in the incidence of hypotension between the dexmedetomidine and propofol sedation regimens (33.3% vs 30.2%, P = .33). However, dexmedetomidine sedation was associated with a higher incidence of bradycardia compared with propofol (9.3% vs 2.9%, P = .005). Interestingly, sensitivity analysis revealed that the incidence of bradycardia was found no difference between the 2 regimens in the studies with low risk of random sequence generation and allocation concealment. These results caution that we should closely monitor blood pressure and electrocardiography (heart rate) regardless of using dexmedetomidine or propofol for sedation.
Atrial fibrillation is the most common complication after cardiac surgery [25] . Although studies demonstrated that dexmedetomidine could reduce myocardial ischemia-reperfusion injury and improve the perfusion of myocardium in patients undergoing cardiac surgery [8, 17] and could decrease catecholamines [26] and inhibit the arrhythmogenic effect of epinephrine [27] , the results were unable to confirm that dexmedetomidine sedation could reduce the incidence of postoperative atrial fibrillation after cardiac surgery compared with propofol.
Although we have adhered to Cochrane methodology and applied TSA to strengthen our conclusions and reduce the risk of random error, there are some potential limitations in the meta-analysis. First, the number of patients in most clinical trials included in the metaanalysis is limited and is thus at risk of overestimating treatment effects and of underestimating adverse effects. Second, there is a large variety of primary end points in the retrieved studies. The selection of patients, the study period, the sedation levels, the definitions of outcomes, and the methods of assessments were also different in these trials, which may affect the precision and reliability of the outcomes. A more controlled research setting may be necessary to accurately evaluate the effects of dexmedetomidine and propofol on outcomes.
In summary, this is the first meta-analysis comparing the effects of dexmedetomidine and propofol sedation on outcomes in patients after cardiac surgery. This study showed that dexmedetomidine Favours dexmedetomidine Favours propofol Fig. 6 . Meta-analysis of bradycardia.
sedation might reduce the risk of POD and shorten the length of intubation. Therefore, dexmedetomidine might be a better choice for sedation in patients after cardiac surgery compared with propofol. However, we still should be vigilant about the risk of hypotension and bradycardia caused by dexmedetomidine. Furthermore, high-quality, large-scale RCTs are still needed to confirm the clinical benefits of dexmedetomidine sedation for patients after cardiac surgery. 
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